Brought to you by 
AveXis nets $98.2mm in IPO
10 Apr 2018
Executive Summary
Gene therapy biotech AveXis Inc. (mostly rare neurological genetic diseases) netted $98.2mm its initial public offering on Nasdaq of 5.3mm shares (including partial exercise of the overallotment) at $20, the mid-point of its anticipated $19-21 range.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AveXis nets $98.2mm in IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice